Nimbus Therapeutics Announces First Patient Dosed in Phase 2b Study of Oral Allosteric TYK2 Inhibitor in Patients with Moderate to Severe Psoriasis
Nimbus Therapeutics Announces First Patient Dosed in Phase 2b Study of Oral Allosteric TYK2 Inhibitor in Patients with Moderate to Severe Psoriasis
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
Imara Presents Clinical Data On Imr-687 In Sickle Cell Disease At The European Hematology Association (Eha) Annual Congress
Imara Presents Clinical Data On Imr-687 In Sickle Cell Disease At The European Hematology Association (Eha) Annual Congress
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma
Imara To Present Clinical Data On Imr-687 In Sickle Cell Disease At The European Hematology Association (Eha) Annual Congress
Imara To Present Clinical Data On Imr-687 In Sickle Cell Disease At The European Hematology Association (Eha) Annual Congress
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform
Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform
Korro Bio Appoints Vineet Agarwal as Chief Financial Officer
Korro Bio Appoints Vineet Agarwal as Chief Financial Officer
PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders
PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders
PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer’s Disease Pathologies
PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer’s Disease Pathologies
Nimbus Therapeutics Expands Development Team to Advance Multiple Portfolio Programs Through Clinical Testing
Nimbus Therapeutics Expands Development Team to Advance Multiple Portfolio Programs Through Clinical Testing
Korro Bio Strengthens Leadership Team with Appointment of Howard Stern M.D., Ph.D. as Chief Scientific Officer
Korro Bio Strengthens Leadership Team with Appointment of Howard Stern M.D., Ph.D. as Chief Scientific Officer
Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer
Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer
Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury
Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury
Volastra Therapeutics Partners with Microsoft to Advance Metastatic Cancer Research
Volastra Therapeutics Partners with Microsoft to Advance Metastatic Cancer Research
Volastra Therapeutics and Dewpoint Therapeutics Partner to Discover Novel Condensate Modulators for Cancer Treatment
Volastra Therapeutics and Dewpoint Therapeutics Partner to Discover Novel Condensate Modulators for Cancer Treatment
Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001
Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001
Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy
Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors
ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
Decibel Therapeutics Announces Pricing of Initial Public Offering
Decibel Therapeutics Announces Pricing of Initial Public Offering
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer
Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated
Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Nimbus Therapeutics Announces First Patient Dosed in Phase 2b Study of Oral Allosteric TYK2 Inhibitor in Patients with Moderate to Severe Psoriasis
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
Imara Presents Clinical Data On Imr-687 In Sickle Cell Disease At The European Hematology Association (Eha) Annual Congress
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform
Korro Bio Appoints Vineet Agarwal as Chief Financial Officer
PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders
Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury
Volastra Therapeutics Partners with Microsoft to Advance Metastatic Cancer Research
Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001
Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy
ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer
Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer